Publication date: December 2026 Source: American Heart Journal Plus: Cardiology Research and Practice, Volume 72 Author(s): Mohamed Doma, Adham Ramadan, Mohammad Hosein Yazdanpanah, Farhan Naeem, Leon M. Ptaszek, Jeremy N. Ruskin
Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes. // American Heart Journal Plus: Cardiology Research and Practice. – URL: https://www.sciencedirect.com/science/article/pii/S2666602226002934?dgcid=rss_sd_all
Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes. American Heart Journal Plus: Cardiology Research and Practice. https://www.sciencedirect.com/science/article/pii/S2666602226002934?dgcid=rss_sd_all
“Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes.” American Heart Journal Plus: Cardiology Research and Practice.
@article{article34191,
title = {Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes},
journal = {American Heart Journal Plus: Cardiology Research and Practice},
url = {https://www.sciencedirect.com/science/article/pii/S2666602226002934?dgcid=rss_sd_all}
}